Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culprits
Jan Thöne, Gisa Ellrichmann Department of Neurology, St Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany Abstract: Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neur...
Main Authors: | Thöne J, Ellrichmann G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-02-01
|
Series: | Drug, Healthcare and Patient Safety |
Online Access: | http://www.dovepress.com/oral-available-agents-in-the-treatment-of-relapsing-remitting-multiple-a12307 |
Similar Items
-
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
by: Roberto Bomprezzi
Published: (2015-01-01) -
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017-07-01) -
Interferons in relapsing remitting multiple sclerosis.
by: Goodin, D
Published: (2003) -
Natalizumab for relapsing-remitting multiple sclerosis
by: A. Horga, et al.
Published: (2011-01-01) -
Disease-modifying therapies in relapsing–remitting multiple sclerosis
by: Fabricio González-Andrade, et al.
Published: (2010-07-01)